by MM360 Staff | Nov 5, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Andrea Lobo | Nov 4, 2025 | Myeloma News
One-time use of CB-011, Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, showed a manageable safety profile and resulted in lasting responses in adults with treatment-resistant or relapsed multiple myeloma. That’s according to the first data from the...
by Marisa Wexler, MS | Nov 4, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to iopofosine I 131 — now being tested in young people in a clinical trial in North America — as a potential treatment for inoperable relapsed or refractory (hard-to-treat)...
by Marisa Wexler, MS | Nov 4, 2025 | Myeloma News
November is Pancreatic Cancer Awareness Month, and advocates nationwide are hosting events to unite the community and raise awareness about the condition. For this year’s campaign, The National Pancreas Foundation is particularly highlighting the importance of early...
by Andrea Lobo | Nov 4, 2025 | Myeloma News
A third dose of CER-1236, Cero Therapeutics’ T-cell therapy candidate for acute myeloid leukemia (AML), was administered to an AML patient taking part in an early clinical trial, with the goal of generating further safety and dosing information. The additional dosing...
